Revision total hip arthroplasty (THA) is associated with increased morbidity, mortality, and healthcare costs due to a technically more demanding surgical procedure when compared with Bio Med Frontiers primary THA. Therefore, a better understanding of risk factors for early revision THA is essential to develop strategies for mitigating the risk of patients undergoing early revision.
This study aimed to develop and validate novel machine learning (ML) models for the prediction of early revision after primary THA.
A total of 7,397 consecutive patients who underwent primary THA were evaluated, including 566 patients (6.6%) with confirmed early revision THA (<2 years from index THA).
Electronic patient records were manually reviewed to identify patient demographics, implant characteristics, and surgical variables that may be associated with early revision THA.
Six ML algorithms were developed to predict early revision THA, and these models were assessed by discrimination, calibration, and decision curve analysis.
The strongest predictors for early revision after primary THA were Charlson Comorbidity Index, body mass index >35 kg/m2, and depression. The six ML models all achieved excellent performance across discrimination (area under the curve >0.80), calibration, and decision curve analysis.
This study developed ML models for the prediction of early revision surgery for patients after primary THA. The study findings show excellent performance on discrimination, calibration, and decision curve analysis for all six candidate models, highlighting the potential of these models to assist in clinical practice patient-specific preoperative quantification of increased risk of early revision THA.
Defining Utility Values for the Chorea Health States in Patients with Huntington’s Disease.
- Chorea is characterized by sudden, involuntary movements that interfere with quality of life (QOL). Utility values measure preferences for different health states and reflect societal perceived disease severity. To date, no studies have reported utility values specifically for Huntington’s disease (HD) chorea.
- We estimated impact on Our supplier QOL of HD chorea severity using utility values from the general population.
- Participants were enrolled using computer-assisted telephone interviews. Participants read vignettes describing four health states for varying levels of chorea severity, with the same underlying HD severity. Time trade-off (TTO) methods were used to estimate utility values, which range from -1 (worse than death) to +1 (perfect health) and represent the number of years in an imperfect health state an individual is willing to give up to live in full health.
- TTO utilities were augmented with visual analog scale (VAS) participant responses. The primary outcome was HD chorea utility estimated by TTO.
- Mean ± SD TTO-derived utility values were 0.07 ± 0.52, 0.26 ± 0.50, 0.48 ± 0.47, and 0.64 ± 0.41 for severe, moderate/severe, moderate/mild, and mild chorea severity, respectively. Differences between each health state and its adjacent less severe health state were statistically significant (all P < 0.0001).
- Respondents were willing to give up 3.6, 5.2, 7.4, and 9.3 years during a 10-year life span to avoid living with mild, mild/moderate, moderate/severe, and severe chorea, respectively. VAS and TTO results were consistent.
- Significant decreases in utility values were seen as HD chorea severity increased. These data can be leveraged for cost-effectiveness modeling to better understand the value of treatments for chorea.
- Utility of gadolinium for identifying the malignant potential of pancreatic cystic lesions.
- To determine if gadolinium is necessary for the diagnosis of a pancreatic cystic lesion (PCL) as benign or malignant by assessing inter-and intra-observer agreement and diagnostic accuracy for the presence of worrisome features/high-risk stigmata on non-contrast MRI compared to MRI with and without contrast, with cytopathology as a reference standard.
- The institutional database was searched to identify consecutive patients that underwent EUS/FNA or surgical resection of an asymptomatic PCL performed from 01/01/2015 to 01/01/2019.
- Two abdominal radiologists independently evaluated PCLs on MRI with all sequences except for contrast-enhanced sequences followed by a second reading with data from the entire MRI including pre- and post-contrast sequences. Cyst size, growth, and the presence of worrisome features/high-risk stigmata were assessed for each cyst on both datasets.
- There were 87 patients with 87 pancreatic cysts; 76(87.4%) were benign and 11 (12.7%) were malignant. The presence of any worrisome features/high-risk stigmata for reader 1 was concordant on both MRIs in 95.4% (83/87; k = 0.874) of cases and for reader 2 was concordant in 96.6% (84/87; k = 0.920) of cases.
- The diagnostic accuracy of the two datasets when the presence of any worrisome feature/high-risk stigmata was predictive of malignancy was identical for reader 1 (AUC = 0.622 for both; p = 1.0) and similar for reader 2 (AUC 0.569 and 0.589; p = 0.08) for both MRI datasets.
- The addition of gadolinium had no significant impact in the diagnosis of a benign versus malignant PCL, with similar intra-observer agreement and diagnostic accuracy for both readers when using contrast-enhanced and unenhanced MRI datasets.
- Utility of GPR68 and TIL in TPF-induced chemotherapy and prognosis evaluation in middle-advanced hypopharyngeal squamous cell carcinoma.
To evaluate the roles of G Protein-Coupled Receptor 68 (GPR68) and tumor infiltrating lymphocytes (TIL) in TPF-(paclitaxel, cisplatin and 5-fluorouracil) induced chemotherapy for middle-advanced hypopharyngeal squamous cell carcinomas.
A total of 31 patients with middle-advanced hypopharyngeal squamous cell carcinoma before TPF-inducted chemotherapy were enrolled from September 2012 to November 2017 in Beijing Tongren Hospital, Capital Medical University, including 28 males and 3 females, aged 43 to 71 years old.
The expression of GPR68 and tumor infiltrating CD4+and CD8+T cells before chemotherapy was detected by immunohistochemical staining, and the relationships between GPR68 expression and clinical features, chemotherapy efficacy and overall survival (OS) were analyzed using t-test.
After 3 cycles of chemotherapy, there were 4, 14, 10 and 3 patients respectively with complete response (CR), partial response (PR), stable disease (SD) and progressive disease (PD).
The positive rates of GPR68 and CD8 were 25% and 40% respectively in the effective group (CR+PR), while 50% and 15% in the ineffective group (SD+PD), with statistically significant differences between two groups (t=5.17 and 12.86,P<0.001). Linear regression analysis showed that GPR68 was negatively correlated with CD8+T cells (r=-0.64,P<0.001).
Utility Box Nalgene 2000ml - EACH |
|||
| BOX1112 | Scientific Laboratory Supplies | EACH | 41.42 EUR |
Utility Carrier Nalgene PP - EACH |
|||
| AUT1680 | Scientific Laboratory Supplies | EACH | 55.35 EUR |
Utility Dipper 316L ss 50ml - EACH |
|||
| SAM1343 | Scientific Laboratory Supplies | EACH | 207.9 EUR |
Utility Dipper 316L ss 100ml - EACH |
|||
| SAM1344 | Scientific Laboratory Supplies | EACH | 228.15 EUR |
Utility Dipper 316L ss 250ml - EACH |
|||
| SAM1345 | Scientific Laboratory Supplies | EACH | 348.3 EUR |
BLANK RED UTILITY TAG 1.5X3 AO LOTO |
|||
| 041924 | BRADY NV | Pack of 1 Tag(s) | 2.17 EUR |
BLANK RED UTILITY TAG 2.5X4 AO LOTO |
|||
| 041925 | BRADY NV | Pack of 1 Tag(s) | 2.35 EUR |
BLANK GRAY UTILITY TAG 1.5X3 AO LOTO |
|||
| 087698 | BRADY NV | Pack of 1 Tag(s) | 2.17 EUR |
BLANK GRAY UTILITY TAG 2.5X4 AO LOTO |
|||
| 087699 | BRADY NV | Pack of 1 Tag(s) | 2.35 EUR |
BLANK BLUE UTILITY TAG 1.5X3 AO LOTO |
|||
| 041926 | BRADY NV | Pack of 1 Tag(s) | 2.17 EUR |
BLANK BLUE UTILITY TAG 2.5X4 AO LOTO |
|||
| 041927 | BRADY NV | Pack of 1 Tag(s) | 2.35 EUR |
Funnel Utility HDPE 3/8in EU - PK72 |
|||
| 4256-0638 | Scientific Laboratory Supplies | PK72 | 1372.95 EUR |
BLANK WHITE UTILITY TAG 1.5X3 AO LOTO |
|||
| 087696 | BRADY NV | Pack of 1 Tag(s) | 2.17 EUR |
BLANK WHITE UTILITY TAG 2.5X4 AO LOTO |
|||
| 087697 | BRADY NV | Pack of 1 Tag(s) | 2.35 EUR |
There was no significant correlation between the CD4 expression and TPF efficacy (P>0.05). The mean OS was 12.5 months in patients with high-expressed GPR68 and 25.0 months in patients with low-expressed GPR68, with a statistically significant difference (P=0.005).
And mean OS was 25.0 months in patients with high-expressed CD8 and 14.5 months in low-expressed CD8, with a statistically significant difference (HR=2.58, P=0.019). Cox regression analysis showed that GPR68 and CD8+T cells were significant prognostic factors (OR(95%CI)=3.27(2.46-5.97) and 1.53(0.78-1.82), all P<0.05), while CD4 had no significant effect on prognosis (P>0.05). GPR68 and CD8+T cells are expected to be biomarkers for evaluating the efficacy and prognosis of TPF-induced chemotherapy in patients with middle-advanced hypopharyngeal squamous cell carcinoma.
